These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 32499266)

  • 1. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis.
    Jin J; Yang L; Liu D; Li W
    BMJ Open; 2020 Jun; 10(6):e035031. PubMed ID: 32499266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis.
    Wang Z; Zhan P; Lv Y; Shen K; Wei Y; Liu H; Song Y
    Transl Lung Cancer Res; 2019 Jun; 8(3):214-226. PubMed ID: 31367535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis.
    Lu Y; Jiang J; Ren C
    PLoS One; 2020; 15(4):e0230979. PubMed ID: 32241019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Yao Y; Yuan D; Liu H; Gu X; Song Y
    Cancer Immunol Immunother; 2013 Mar; 62(3):471-9. PubMed ID: 22986452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of neutrophil-to-lymphocyte ratio for nasopharyngeal carcinoma: A meta-analysis.
    Yin J; Qin Y; Luo YK; Feng M; Lang JY
    Medicine (Baltimore); 2017 Jul; 96(29):e7577. PubMed ID: 28723793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies.
    Mei Z; Shi L; Wang B; Yang J; Xiao Z; Du P; Wang Q; Yang W
    Cancer Treat Rev; 2017 Jul; 58():1-13. PubMed ID: 28602879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.
    Platini H; Ferdinand E; Kohar K; Prayogo SA; Amirah S; Komariah M; Maulana S
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis.
    Jiang T; Qiao M; Zhao C; Li X; Gao G; Su C; Ren S; Zhou C
    Cancer Immunol Immunother; 2018 May; 67(5):713-727. PubMed ID: 29423649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy.
    Viñal D; Gutierrez-Sainz L; Martinez D; Garcia-Cuesta JA; Pedregosa J; Villamayor J; Ostios L; Sanchez-Cabrero D; Higuera O; Pinto A; Rodriguez-Salas N; Espinosa E; de Castro J; Feliu J
    Clin Transl Oncol; 2021 Jun; 23(6):1185-1192. PubMed ID: 33226553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis.
    Matsas S; Aguiar PN; Del Giglio A
    J Gastrointest Oncol; 2024 Feb; 15(1):33-51. PubMed ID: 38482212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients.
    Yu Y; Qian L; Cui J
    Mol Clin Oncol; 2017 Sep; 7(3):498-506. PubMed ID: 28811903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy.
    Li Y; Meng Y; Sun H; Ye L; Zeng F; Chen X; Deng G
    J Immunother; 2022 Jan; 45(1):43-50. PubMed ID: 34510106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictability of Neutrophile to Lymphocyte Ratio and Platelet to Lymphocyte Ratio on the Effectiveness of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer patients: A Meta-Analysis.
    Nguyen CTT; Van TNK; Huong PT
    Cancer Control; 2024; 31():10732748241285474. PubMed ID: 39285591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.